We have previously reported the first case of a patient with resectable metastatic HER2-positive and MSS colon cancer who achieved a pathologic complete response (pCR) to neoadjuvant chemotherapy combined with dual anti-HER2 treatment, namely trastuzumab and pertuzumab [4]. The gene discussed is ERBB2; the disease is malignant colon neoplasm.